Primary aldosteronism is an underdiagnosed cause of hypertension, occurring in one out of seven hypertensive patients. Traditional treatments have limitations, particularly spironolactone, which can cause side effects such as gynecomastia and erectile dysfunction. In a study involving 15 patients, baxdrostat effectively blocked aldosterone overproduction. After 12 weeks of treatment, average systolic blood pressure dropped by nearly 25 mm Hg, with 73 percent of patients achieving target blood pressure levels. Aldosterone levels also decreased significantly, exceeding the effects of surgery. Some patients showed transient declines in kidney function during follow-up.
In the study, investigators treated 15 patients with primary aldosteronism with baxdrostat, a new drug designed to block the overproduction of aldosterone with high specificity.
After 12 weeks, investigators found that the average systolic blood pressure dropped by nearly 25 mm Hg, a reduction rarely seen in hypertension trials, and 73 percent of patients reached the target blood pressure of under 140/90 mm Hg.
There was also a 97 percent median reduction in the aldosterone levels, surpassing even the effects of adrenal gland surgery.
Collection
[
|
...
]